Seven commercial AI devices for lung cancer detection on chest x-rays show substantial and clinically meaningful performance variability.
Key Details
- 1Seven commercial AI tools were evaluated on 5,235 chest x-rays in a UK single-center study.
- 2Sensitivity ranged from 20.8% to 77.8%; specificity from 58.9% to 98.4%; positive predictive value from 1.5% to 28.4%.
- 3Significant differences were observed in 39 of 44 pairwise comparisons between devices.
- 4Three devices detected more tumors than radiologists; four detected fewer.
- 5False positives for tumor detection ranged widely (10 to 2,039 cases per device).
- 6Minimal agreement among devices (Fleiss κ = 0.24) highlights inconsistent results.
Why It Matters
The wide variability in performance among commercial AI products raises critical questions about device selection, safety, and standardization in clinical radiology. Establishing robust benchmarking and reporting frameworks is essential for effective and safe AI adoption in imaging.
Source
AuntMinnie
Related News
•Radiology Business
RadNet AI Tool Reduces Unnecessary Prostate Biopsies by 19%
RadNet's DeepHealth AI tool can help avoid nearly 1 in 5 prostate biopsies while maintaining high cancer detection sensitivity.
•Radiology Business
Multi-Vendor AI Adoption Delivers Efficiency Gains in Private Radiology
A large-scale European study shows that adopting multiple AI tools in private radiology practices leads to significant efficiency improvements.
•Radiology Business
Harrison.ai Cuts 15% Staff as Revenue and U.S. Expansion Accelerate
Radiology AI firm Harrison.ai reduces staffing by 15% amid quadrupling revenue and major U.S. expansion.